PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.
The term “pemphigus” refers to a group of organ-specific, rare, autoimmune diseases that cause blistering of the skin. Pemphigus foliaceus (PF) is the second most common form of pemphigus. It is ...
Rituximab may be a preferred treatment option vs first-line corticosteroid-sparing agents for patients with pemphigus who are at risk for cardiovascular and metabolic conditions, according to study ...
In a paper published in this journal, Szabolcs et al 1 reported the unusual case of a young boy who experienced bullous pemphigoid in association with chronic graft-versus-host disease (GVHD) after ...
Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...
BOSTON--(BUSINESS WIRE)--Syntimmune, Inc., a clinical-stage biotechnology company developing antibody therapeutics targeting FcRn, today announced positive preliminary results from its Phase 1b ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The conventional treatment mainstays for pemphigus are problematic during the COVID-19 pandemic, ...
DSG3-CAART is designed to selectively target the cause of mucosal pemphigus vulgaris. The Food and Drug Administration (FDA) has granted Fast Track designation to DSG3-CAART (desmoglein 3 chimeric ...
PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback